CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced that Dr. Martin Madaus will be joining as the company’s Chief Operations Officer to assist in the rapid expansion of Sherlock in the next 12 months. Dr. Madaus brings to Sherlock nearly 30 years of industry experience leading diagnostics companies across all stages of development through commercialization. He will lead Sherlock’s business operations functions while supporting the company to scale to a fully functional commercial organization.
“Martin has led an illustrious career with roles at the forefront of both diagnostics powerhouses and the most promising early-stage companies,” said Rahul Dhanda, Co-founder, President and CEO of Sherlock Biosciences. “With one of the most successful track records in all of diagnostics, Martin is an invaluable addition to Sherlock’s leadership as we scale development of our internal and partner development programs, including SHERLOCK CRISPR-based products and launching INSPECTR, our at-home, instrument-free rapid diagnostic, next year.”
Most recently, Dr. Madaus served as Interim CEO and Executive Chairman at Ultivue Inc. and Emulate Bio. He also served as Chairman and Chief Executive Officer of Ortho Clinical Diagnostics from 2014 to 2019, leading the buy-out through the Carlyle Group, where he continues to serve as Operating Executive. Previously, he was President, Chairman and CEO of Millipore Corporation, which was acquired by Merck KGaA, and CEO of Roche Diagnostics North America. He began his career in diagnostics in Germany. Dr. Madaus has extensive public and private company board experience and currently serves on the boards of Quanterix Corporation, Ultivue, Emulate Bio and Candela Medical. Dr. Madaus holds a D.V.M. from the University of Munich and a Ph.D. in veterinary medicine from the University of Veterinary Medicine Hannover in Germany.
“Sherlock’s powerful engineering biology tools hold the promise to enable the development of next-generation molecular diagnostics systems that are accurate, simple and affordable,” said Dr. Madaus. “The global COVID-19 pandemic has shown that major gaps exist in our tools to detect and monitor important pathogens impacting people around the world. I am excited to help with scaling up a company that has the near-term potential to make a major contribution to solving the testing challenges by making simple and accurate testing methods widely available, and I look forward to working closely with Rahul and the rest of the team.”
About Sherlock Biosciences
Sherlock Biosciences is dedicated to making molecular diagnostics better, faster and more affordable through Engineering Biology platforms. The company is developing applications of SHERLOCK™, a CRISPR-based method to detect and quantify specific genetic sequences, and INSPECTRTM, a Synthetic Biology-based molecular diagnostics platform that is instrument-free. SHERLOCK and INSPECTR can be used in virtually any setting without complex instrumentation, opening up a wide range of potential applications in areas including precision oncology, infection identification, food safety, at-home tests, and disease detection in the field. In May 2020, the company received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Sherlock™ CRISPR SARS-CoV-2 kit, the first FDA-authorized use of CRISPR technology. For more information visit Sherlock.bio.
